After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor ...

The National Health Insurance Authority on Thursday announced that its enrolment portal has been restored and is now fully ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients ...

Q3 2025 Earnings Call Transcript October 28, 2025 Novartis AG misses on earnings expectations. Reported EPS is $2.25 EPS, ...

Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its results1 for the nine-month period ended September 30, 2025, and third quarter 2025 (3Q25). Solid financial performance with a ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

The Center for American Progress recently hosted a summit with more than 50 advocates from the reproductive and disability ...

Veterans across the country are reporting cancelled appointments, shortened treatment plans, and new limits on one-on-one ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

CNW/ - Restaurant Brands International Inc. ("RBI") (NYSE: QSR) (TSX: QSR) (TSX: QSP) today reported financial results for ...